HCC therapies—lessons learned (original) (raw)

• Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011).
  PubMed Google Scholar
• Worns, M. A., Weinmann, A., Schuchmann, M. & Galle, P. R. Systemic therapies in hepatocellular carcinoma. Dig. Dis. 27, 175–188 (2009).
  Article PubMed Google Scholar
• Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
  Article CAS PubMed Google Scholar
• Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia–Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25–34 (2009).
  Article CAS PubMed Google Scholar
• Bruix, J. & Sherman, M. Management of hepatocellular carcinoma: an update. Hepatology 53, 1020–1022 (2011).
  Article PubMed Google Scholar
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908–943 (2012).
• Worns, M. A. & Galle, P. R. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin. Investig. Drugs 19, 615–629 (2010).
  Article PubMed Google Scholar
• Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698–711 (2008).
  Article PubMed Google Scholar
• Worns, M. A. Systemic therapy and synergies by combination. Dig. Dis. 31, 104–111 (2013).
  Article PubMed Google Scholar
• Cheng, A. L. et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J. Clin. Oncol. 31, 4067–4075 (2013).
  Article CAS PubMed Google Scholar
• Cainap, C. et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) [abstract]. J. Clin. Oncol. 30 (Suppl. 34), 249 (2013).
  Article Google Scholar
• Johnson, P. J. et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 31, 3517–3524 (2013).
  Article CAS PubMed Google Scholar
• Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52–60 (2010).
  Article CAS PubMed Google Scholar
• Zhu, A. X. et al. SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma (HCC) [abstract]. Eur. J. Cancer 48 (Suppl.) 2 (2012).
  Google Scholar
• Qin, S. et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol. 31, 3501–3508 (2013).
  Article CAS PubMed Google Scholar
• Llovet, J. M. et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J. Clin. Oncol. 31, 3509–3516 (2013).
  Article CAS PubMed Google Scholar
• Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival. Novartis [online], (2013).
• Worns, M. A. & Galle, P. R. Future perspectives in hepatocellular carcinoma. Dig. Liver Dis. 42 (Suppl. 3), S302–S309 (2010).
  Article PubMed Google Scholar
• Villanueva, A. & Llovet, J. M. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin. Cancer Res. 18, 1824–1826 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Villanueva, A. Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach. J. Hepatol. 59, 392–395 (2013).
  Article PubMed Google Scholar
• Kelley, R. K. & Venook, A. P. Novel therapeutics in hepatocellular carcinoma. Am. Soc. Clin. Oncol. Educ. Book 2013, 137–142 (2013).
  Article Google Scholar
• Llovet, J. M., Bru, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19, 329–338 (1999).
  Article CAS PubMed Google Scholar
• Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245–1255 (2012).
  Article PubMed Google Scholar
• Villanueva, A., Newell, P., Chiang, D. Y., Friedman, S. L. & Llovet, J. M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27, 55–76 (2007).
  Article CAS PubMed Google Scholar
• Weinstein, I. B. & Joe, A. Oncogene addiction. Cancer Res. 68, 3077–3080 (2008).
  Article CAS PubMed Google Scholar
• Shaw, A. T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385–2394 (2013).
  Article CAS PubMed Google Scholar
• Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Marquardt, J. U. & Andersen, J. B. Next-generation sequencing: application in liver cancer—past, present and future? Biology (Basel) 1, 383–394 (2012).
  Google Scholar
• Schirmacher, P. et al. Fighting the bushfire in HCC trials. J. Hepatol. 55, 276–277 (2011).
  Article PubMed Google Scholar
• Villanueva, A. & Llovet, J. M. Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. Hepatology 56, 2416–2419 (2012).
  Article CAS PubMed Google Scholar
• Pantel, K. & Alix-Panabieres, C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res. 73, 6384–6388 (2013).
  Article CAS PubMed Google Scholar
• Santoro, A. et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 14, 55–63 (2013).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online], (2013).
• Schmieder, R. et al. Allosteric MEK1/2 inhibitor refametinib (BAY 86–9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia 15, 1161–1171 (2013).
  Article PubMed PubMed Central Google Scholar
• Zhu, A. X. et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 19, 920–928 (2013).
  Article CAS PubMed Google Scholar
• Catalogue of Somatic Mutations in Cancer [online].
• Assenat, E. et al. Sorafenib alone versus sorafenib combined with gemcitabine and oxaliplatin (GEMOX) in the first-line treatment of advanced hepatocellular carcinoma: final results of the randomized phase II GoNext trial (a UNICANCER/FFCD/PRODIGE 10 study) [abstract]. Eur. J. Cancer 49 (Suppl. 2), 2467 (2013).
  Google Scholar
• US National Library of Medicine ClinicalTrials.gov [online], (2013).
• Llovet, J. M., Burroughs, A. & Bruix, J. Hepatocellular carcinoma. Lancet 362, 1907–1917 (2003).
  Article PubMed Google Scholar
• ArQule Announces Third Quarter Fiscal 2013 Results. Arqule [online], (2013).
• Reig, M. et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second line trial design. Hepatology 58, 2023–2031 (2013).
  Article CAS PubMed Google Scholar
• Kelley, R. K. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials. J. Clin. Oncol. 31, 3483–3486 (2013).
  Article CAS PubMed Google Scholar
• Shao, Y. Y. et al. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. J. Hepatol. 60, 313–318 (2014).
  Article PubMed Google Scholar
• He, A. R. & Goldenberg, A. S. Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therap. Adv. Gastroenterol. 6, 447–458 (2013).
  Article PubMed PubMed Central Google Scholar
• US National Library of Medicine. ClinicalTrials.gov [online], (2013).
• US National Library of Medicine. ClinicalTrials.gov [online], (2013).
• US National Library of Medicine. ClinicalTrials.gov [online], (2013).
• US National Library of Medicine. ClinicalTrials.gov [online], (2014).
• US National Library of Medicine. ClinicalTrials.gov [online], (2014).